Title |
Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
|
---|---|
Published in |
Journal of Hematology & Oncology, January 2013
|
DOI | 10.1186/1756-8722-6-2 |
Pubmed ID | |
Authors |
Mohamed A Kharfan-Dabaja, Mehdi Hamadani, Tea Reljic, Taiga Nishihori, William Bensinger, Benjamin Djulbegovic, Ambuj Kumar |
Abstract |
Despite advances in understanding of clinical, genetic, and molecular aspects of multiple myeloma (MM) and availability of more effective therapies, MM remains incurable. The autologous-allogeneic (auto-allo) hematopoietic cell transplantation (HCT) strategy is based on combining cytoreduction from high-dose (chemo- or chemoradio)-therapy with adoptive immunotherapy. However, conflicting results have been reported when an auto-allo HCT approach is compared to tandem autologous (auto-auto) HCT. A previously published meta-analysis has been reported; however, it suffers from serious methodological flaws. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
Unknown | 47 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 17% |
Other | 7 | 15% |
Researcher | 7 | 15% |
Student > Bachelor | 3 | 6% |
Professor | 2 | 4% |
Other | 9 | 19% |
Unknown | 12 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 22 | 46% |
Agricultural and Biological Sciences | 4 | 8% |
Biochemistry, Genetics and Molecular Biology | 2 | 4% |
Nursing and Health Professions | 2 | 4% |
Economics, Econometrics and Finance | 1 | 2% |
Other | 3 | 6% |
Unknown | 14 | 29% |